Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Add To Watchlist

Recent & Breaking News (OTCQX:CSLLY)

Hemophilia Association Of New Jersey Recognizes CSL CEO Paul Perreault As "Humanitarian Man Of The Year"

PR Newswire May 14, 2018

Patient Advocacy Groups Focus On Key Issues Affecting Patients

PR Newswire April 26, 2018

CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting

PR Newswire April 20, 2018

The Lancet publishes results demonstrating adjuvanted quadrivalent influenza vaccine provides significantly greater efficacy in children 6 through 23 months

PR Newswire April 19, 2018

Nasdaq Hosted 2nd Nasdaq International Designation Virtual Investor Conference

GlobeNewswire April 3, 2018

CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors

PR Newswire March 23, 2018

Forbes Magazine Names CSL Limited Among Top 50 Employers in the World

PR Newswire March 20, 2018

FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PR Newswire March 16, 2018

CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks

PR Newswire March 15, 2018

CSL CEO Paul Perreault Calls on Industry to Improve Patients' Access to Medicines

PR Newswire Europe Non Regulatory March 13, 2018

CSL and Vitaeris Announce Strategic Partnership with Option to Acquire

PR Newswire December 5, 2017

CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy

PR Newswire December 4, 2017

Be FLUent Partnership Shines Spotlight on Importance of Flu Prevention in Seniors

PR Newswire December 4, 2017

Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

PR Newswire November 9, 2017

Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting

PR Newswire October 29, 2017

New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

PR Newswire October 24, 2017

CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same

PR Newswire October 12, 2017

Japan's Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

PR Newswire September 28, 2017

Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders

PR Newswire September 28, 2017

CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State

PR Newswire September 19, 2017